Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio

Recent News

Teligent Announces Strategic Review

BUENA, N.J. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Teligent Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic phar...

Learn More

Teligent, Inc. Announces Second Quarter 2019 Results

BUENA, N.J. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...

Learn More

Teligent, Inc. to Hold Conference Call for Second Quarter 2019 Results on Monday August 5th, 2019

BUENA, N.J. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Investor Overview